UNCY — Unicycive Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSmall Cap
Brief: Unicycive Reports Key Findings Of Uni-494 Efficacy In Preclinical Animal Model Of Geographic Atrophy
Brief: Unicycive Announces Third Quarter Financial Results
Brief: Unicycive Completes Enrollment For An Investigational Treatment Of Hyperphosphatemia In Dialysis Patients
U.S. STOCKS ON THE MOVE-Pinterest, Aemetis, Walmart
U.S. STOCKS ON THE MOVE-Twitter, ChargePoint, IMAX
U.S. STOCKS ON THE MOVE-Biophytis, Gold miners, Imara
Unicycive gains on promising data from kidney disease drug's pre-clinical study
Brief: Unicycive Reports Key Findings Of Uni-494 Efficacy In Preclinical Animal Model Of Acute Kidney Injury (Aki)
Brief: Unicycive Therapeutics Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing
Brief: Unicycive Announces Q2 Results
Brief: Unicycive Announces Exclusive License And Development Agreement With Lee’S Pharmaceutical Holdings Limited For Renazorb In China And Certain Other Asian Markets
Brief: Unicycive Initiates Pivotal Clinical Bioequivalence Study Of Renazorb To Treat Hyperphosphatemia
Brief: Unicycive Announces First Quarter Financial Results And Provides Business Update
Brief: Unicycive Announces Full Year 2021 Financial Results
Brief: Unicycive Announces Acceptance Of Two Preclinical Data Sets To Be Presented At European Renal Association Congress
Brief: Unicycive Therapeutics Receives Confirmatory Guidance On Renazorb Regulatory Pathway
Brief: Unicycive Therapeutics Announces Q3 Loss Per Share Of $0.37
Brief: Unicycive Therapeutics Inc Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy
Brief: Unicycive Therapeutics To Be Added To Russell Microcap Index